论文部分内容阅读
目的:探讨手术去势间断联合抗雄激素药物治疗晚期前列腺癌的临床疗效。方法:选择2014年2月~2016年2月收治于我院的30例晚期前列腺癌患者作为研究对象,将其随机分组,分为对照组(15例)和研究组(15例),对照组患者采用抗雄激素药物进行治疗,研究组采用手术去势间断联合抗雄激素药物进行治疗,对比研究组和对照组两组患者的治疗效果。结果:比较研究组和对照组治疗前后PSA水平,治疗前期两组患者PSA水平无显著差异(P>0.05),不具有统计学意义;治疗后实验组患者PSA水平明显低于对照组,差异具有统计学意义(P<0.05);比较研究组和对照组患者的疾病无进展生存时间(PFS time)和总生存时间(Os time),研究组均优于对照组,差异具有统计学意义(P<0.05)。结论:手术去势间断联合抗雄激素药物治疗晚期前列腺癌的临床效果较好,值得临床推广。
Objective: To investigate the clinical efficacy of surgical castration and anti-androgen therapy in the treatment of advanced prostate cancer. Methods: Thirty patients with advanced prostate cancer admitted to our hospital from February 2014 to February 2016 were randomly divided into control group (15 cases), study group (15 cases), control group The patients were treated with anti-androgen drugs. The study group was treated with surgical castration and intermittent anti-androgen therapy, and compared the therapeutic effect between the two groups in study group and control group. Results: There was no significant difference in the level of PSA between the two groups before and after treatment (P> 0.05). The level of PSA in the experimental group was significantly lower than that in the control group (P <0.05). Compared with the control group, the PFS time and the OS time of the study group and the control group were statistically significant (P <0.05). Conclusion: The clinical effect of surgical castration combined with anti-androgen therapy in the treatment of advanced prostate cancer is better and worthy of clinical promotion.